Detalhe da pesquisa
1.
Clinical features, therapeutic choice and response by phototype in psoriasis: analysis of the French PsoBioTeq cohort.
Clin Exp Dermatol
; 48(11): 1238-1246, 2023 Oct 25.
Artigo
Inglês
| MEDLINE | ID: mdl-37409606
2.
Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Patients with Psoriasis from the PsoBioTeq Cohort.
Acta Derm Venereol
; 102: adv00665, 2022 Mar 08.
Artigo
Inglês
| MEDLINE | ID: mdl-34806759
3.
First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort Psobioteq.
Dermatology
; 237(3): 338-346, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-33535213
4.
Biologic tapering for patients with psoriasis with low disease activity: data from the French PsoBioTeq Registry.
Br J Dermatol
; 188(1): 150-152, 2023 01 23.
Artigo
Inglês
| MEDLINE | ID: mdl-36689510
5.
Quantitative Benefit-Risk Models Used for Rotavirus Vaccination: A Systematic Review.
Open Forum Infect Dis
; 7(4): ofaa087, 2020 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-32296726
6.
Using Discretely Integrated Condition Event Simulation To Construct Quantitative Benefit-Risk Models: The Example of Rotavirus Vaccination in France.
Clin Ther
; 42(10): 1983-1991.e2, 2020 10.
Artigo
Inglês
| MEDLINE | ID: mdl-32988633
7.
Benefit-Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit-Risk Models Applied to Vaccines.
Drug Saf
; 43(11): 1089-1104, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32914292
8.
Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC).
Drug Saf
; 43(11): 1105-1120, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32918682
9.
Benefit Versus Risk Assessment of Rotavirus Vaccination in France: A Simulation and Modeling Analysis.
BioDrugs
; 32(2): 139-152, 2018 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-29589230